Imsidolimab (ANB 019) is a high-affinity, humanized monoclonal antibody of anti- IL-36R. Imsidolimab antagonizes IL-36 cytokine signal transduction. Imsidolimab has potential application in generalized pustular psoriasis (GPP) and other inflammatory skin diseases [1] [2].
References:
[1]. Gudjonsson J E, et al. 34617 Imsidolimab in the treatment of adult subjects with generalized pustular psoriasis: Design of a pivotal phase 3 clinical trial and a long-term extension study[J]. Journal of the American Academy of Dermatology, 2022, 87(3): AB70.
[2]. Iznardo H, et al. Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease. Int J Mol Sci. 2021 Apr 21;22(9):4344.
References:
[1]. Gudjonsson J E, et al. 34617 Imsidolimab in the treatment of adult subjects with generalized pustular psoriasis: Design of a pivotal phase 3 clinical trial and a long-term extension study[J]. Journal of the American Academy of Dermatology, 2022, 87(3): AB70.
[2]. Iznardo H, et al. Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease. Int J Mol Sci. 2021 Apr 21;22(9):4344.